This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
by Zacks Equity Research
EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
EYPTPositive Net Change REGNPositive Net Change BAYRYPositive Net Change AMRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Best Growth Stocks to Buy for August 18th
by Zacks Equity Research
CNC, ATI and MNDY made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 18, 2026
ATINegative Net Change CNCPositive Net Change MNDYPositive Net Change
aerospace computers medical
Is ISRG's Software Strategy Becoming as Important as Its Robots?
by Indrajit Bandyopadhyay
ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.
ISRGPositive Net Change SYKNegative Net Change ZBHPositive Net Change
medical medical-devices robotics smart-health
UHS Adds Talkspace to Accelerate Virtual Behavioral Health Growth
by Zacks Equity Research
Universal Health's $835M Talkspace acquisition expands virtual behavioral health, adding 6,000 providers and new growth opportunities.
UHSPositive Net Change THCPositive Net Change TALKNo Net Change BTSGNegative Net Change
medical
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
by Santanu Roy
Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
CATNegative Net Change FETNegative Net Change HCSGPositive Net Change CDNANegative Net Change AMRXNegative Net Change
business-services industrial-products medical oil-energy
HSIC Raises 2026 Outlook as Sales and Margin Momentum Accelerates
by Moumi Mondal
Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings execution remains key to sustaining earnings momentum.
HSICNegative Net Change XRAYNegative Net Change COOPositive Net Change
medical medical-devices
How Should You Approach CVS Health Stock After Q2 Earnings?
by Moumi Mondal
CVS delivers strong Q2 growth and raises 2026 targets, but Caremark pressures and medical costs are likely to shape its next move.
CVSPositive Net Change UNHNegative Net Change ELVPositive Net Change
medical medical-devices
New Strong Buy Stocks for August 18th
by Zacks Equity Research
ALGT, HMC, INSP, AII and ALL have been added to the Zacks Rank #1 (Strong Buy) List on August 18, 2026.
ALLPositive Net Change HMCPositive Net Change ALGTNegative Net Change INSPPositive Net Change AIIPositive Net Change
auto-tires-trucks insurance medical transportation
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
by Indrajit Bandyopadhyay
CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
CNMDPositive Net Change MDTPositive Net Change SYKNegative Net Change
medical medical-devices
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?
by Indrajit Bandyopadhyay
CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
CNMDPositive Net Change MDTPositive Net Change SYKNegative Net Change
medical medical-devices